Abeona Therapeutics Company Leadership
| ABEO Stock | USD 6.39 0.02 0.31% |
About 75 percent of all Abeona Therapeutics' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Abeona Therapeutics suggests that quite a few insiders are very bullish. Abeona Therapeutics employs about 84 people. The company is managed by 12 executives with a total tenure of roughly 196 years, averaging almost 16.0 years of service per executive, having 7.0 employees per reported executive.
Abeona Therapeutics' Insider Buying Vs Selling
75
Selling | Buying |
Latest Trades
| 2024-05-16 | Leila Alland | Acquired 11000 @ 4.71 | View | ||
| 2024-04-26 | Faith L Charles | Acquired 7550 @ 3.28 | View | ||
| 2024-04-25 | Vishwas Seshadri | Acquired 10000 @ 3.2 | View | ||
| 2024-01-17 | Mark Alvino | Disposed 7084 @ 5.11 | View |
Monitoring Abeona Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Abeona |
Abeona Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Abeona Therapeutics' future performance. Based on our forecasts, it is anticipated that Abeona will maintain a workforce of about 80 employees by January 2025.Abeona Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.3781) % which means that it has lost $0.3781 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2738) %, meaning that it created substantial loss on money invested by shareholders. Abeona Therapeutics' management efficiency ratios could be used to measure how well Abeona Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 1st of December 2024, Return On Tangible Assets is likely to drop to -0.89. In addition to that, Return On Capital Employed is likely to grow to -0.89. At this time, Abeona Therapeutics' Other Current Assets are very stable compared to the past year. As of the 1st of December 2024, Non Currrent Assets Other is likely to grow to about 319.9 K, while Total Assets are likely to drop about 49.3 M.As of the 1st of December 2024, Common Stock Shares Outstanding is likely to grow to about 22.4 M, while Net Loss is likely to drop (41.1 M).
Abeona Therapeutics Workforce Comparison
Abeona Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 2,740. Abeona Therapeutics holds roughly 84.0 in number of employees claiming about 3% of equities under Health Care industry.
Abeona Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Abeona Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Abeona Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Abeona Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-09-01 | 3.4 | 17 | 5 | 916,425 | 33,316 |
| 2024-06-01 | 1.0 | 6 | 6 | 2,991,233 | 118,394 |
| 2024-03-01 | 0.25 | 1 | 4 | 20,000 | 8,062 |
| 2023-09-01 | 0.3636 | 4 | 11 | 26,000 | 61,884 |
| 2023-06-01 | 2.25 | 9 | 4 | 921,770 | 2,156 |
| 2022-12-01 | 3.0 | 3 | 1 | 15,869 | 207.00 |
| 2022-03-01 | 1.0 | 1 | 1 | 200,000 | 0.00 |
| 2021-12-01 | 0.2857 | 2 | 7 | 350,000 | 122,826 |
| 2021-09-01 | 1.0 | 4 | 4 | 1,122,000 | 195,409 |
| 2021-06-01 | 6.3333 | 19 | 3 | 1,752,092 | 135,445 |
| 2021-03-01 | 0.8333 | 15 | 18 | 1,866,911 | 1,688,057 |
| 2020-12-01 | 0.7368 | 28 | 38 | 3,739,859 | 3,923,947 |
| 2020-03-01 | 4.0 | 4 | 1 | 434,192 | 6,446 |
| 2019-12-01 | 1.0 | 1 | 1 | 200,000 | 19,827 |
| 2019-03-01 | 1.0 | 3 | 3 | 190,000 | 235,000 |
| 2018-12-01 | 1.0 | 1 | 1 | 35,000 | 180,000 |
| 2018-06-01 | 2.0 | 2 | 1 | 60,000 | 30,000 |
| 2018-03-01 | 2.0 | 2 | 1 | 350,000 | 0.00 |
| 2014-12-01 | 3.4286 | 24 | 7 | 28,270,701 | 3,654 |
| 2012-12-01 | 2.3333 | 7 | 3 | 21,369,270 | 1,366,970 |
| 2012-06-01 | 0.75 | 3 | 4 | 100,700 | 345,457 |
| 2012-03-01 | 1.5 | 3 | 2 | 30,300 | 16,000 |
| 2008-12-01 | 1.5 | 3 | 2 | 333,706 | 333,533 |
| 2008-03-01 | 6.75 | 27 | 4 | 3,308,276 | 769,569 |
| 2007-12-01 | 3.1667 | 19 | 6 | 3,947,293 | 1,374,837 |
| 2007-06-01 | 1.0 | 1 | 1 | 60,000 | 20,000 |
| 2007-03-01 | 0.8571 | 6 | 7 | 631,040 | 12,840 |
| 2005-06-01 | 1.0 | 1 | 1 | 9,000 | 30,000 |
| 2005-03-01 | 1.0 | 1 | 1 | 30,200 | 30,200 |
Abeona Therapeutics Notable Stakeholders
An Abeona Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Abeona Therapeutics often face trade-offs trying to please all of them. Abeona Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Abeona Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Vishwas MBA | CEO President | Profile | |
| Madhav MBA | Chief VP | Profile | |
| Joseph Vazzano | Chief Officer | Profile | |
| Dmitriy MD | Chief Officer | Profile | |
| Brian Kevany | CTO VP | Profile | |
| Carl Denny | Senior Affairs | Profile | |
| Alison Hardgrove | Vice Resources | Profile | |
| Scott Santiamo | Director Communications | Profile | |
| Joseph CPA | Chief Officer | Profile | |
| Gregory Gin | Vice Communications | Profile | |
| Jon Voss | VP Quality | Profile | |
| Dr JD | Senior Counsel | Profile |
About Abeona Therapeutics Management Performance
The success or failure of an entity such as Abeona Therapeutics often depends on how effective the management is. Abeona Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Abeona management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Abeona management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.85) | (0.89) | |
| Return On Capital Employed | (0.93) | (0.89) | |
| Return On Assets | (0.85) | (0.89) | |
| Return On Equity | (3.65) | (3.84) |
Abeona Therapeutics Workforce Analysis
Traditionally, organizations such as Abeona Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Abeona Therapeutics within its industry.Abeona Therapeutics Manpower Efficiency
Return on Abeona Therapeutics Manpower
| Revenue Per Employee | 41.7K | |
| Revenue Per Executive | 291.7K | |
| Net Loss Per Employee | 645.1K | |
| Net Loss Per Executive | 4.5M | |
| Working Capital Per Employee | 503.8K | |
| Working Capital Per Executive | 3.5M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abeona Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abeona Therapeutics. If investors know Abeona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abeona Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.05) | Quarterly Revenue Growth (1.00) | Return On Assets (0.38) | Return On Equity (1.27) |
The market value of Abeona Therapeutics is measured differently than its book value, which is the value of Abeona that is recorded on the company's balance sheet. Investors also form their own opinion of Abeona Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Abeona Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abeona Therapeutics' market value can be influenced by many factors that don't directly affect Abeona Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abeona Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abeona Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abeona Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.